These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 936381)

  • 41. Chemotherapy of advanced prostatic cancer with adriamycin, BCNU, and cyclophosphamide.
    Presant CA; Van Amburg A; Klahr C; Metter GE
    Cancer; 1980 Dec; 46(11):2389-92. PubMed ID: 7438014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proceedings: Rationale and results of primary endocrine therapy in patients with prostatic cancer.
    Scott WW
    Cancer; 1973 Nov; 32(5):1119-25. PubMed ID: 4796581
    [No Abstract]   [Full Text] [Related]  

  • 43. Chemotherapy of advanced prostatic cancer by the National Prostatic Cancer Group.
    Murphy GP; Saroff J; Joiner JR; Prout GR; Gibbons RP; Schmidt JD; Johnson DE; Scott WW
    Semin Oncol; 1976 Jun; 3(2):103-6. PubMed ID: 132703
    [No Abstract]   [Full Text] [Related]  

  • 44. Changes in 87mSr concentractions in skeletal metastases in patients responding to cyclical combination chemotherapy for advanced breast cancer.
    Gillespie PJ; Alexander JL; Edelstyn GA
    J Nucl Med; 1975 Mar; 16(3):191-3. PubMed ID: 1113166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
    Ottosson S; Magnusson K; Hultborn R
    Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
    Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An aggressive approach to prostatic cancer.
    Alyea EP; Dees JE; Glenn JF
    J Urol; 1977 Jul; 118(1 Pt 2):211-5. PubMed ID: 327106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide: methods of documenting tumor response and progression.
    Ihde DC; Bunn PA; Cohen MH; Dunnick NR; Eddy JL; Minna JD
    Cancer; 1980 Mar; 45(6):1300-10. PubMed ID: 7357521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The chemotherapy of prostatic carcinoma.
    Beckley S; Wajsman Z; Slack N; Mittelman A; Murphy GP
    Scand J Urol Nephrol Suppl; 1980; 55():151-62. PubMed ID: 6938019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease.
    Citrin DL; Elson P; DeWys WD
    Cancer; 1984 Jul; 54(1):13-7. PubMed ID: 6372984
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Chemotherapy of advanced prostate cancer].
    Murphy GP
    Vopr Onkol; 1977; 23(12):26-38. PubMed ID: 146305
    [No Abstract]   [Full Text] [Related]  

  • 52. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Kasimis BS; Miller JB; Kaneshiro CA; Forbes KA; Moran EM; Metter GE
    J Clin Oncol; 1985 Mar; 3(3):385-92. PubMed ID: 3838343
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective].
    Tanaka T; Tanino H; Hirai I; Hata K; Maebeya S; Oota F; Miki Y
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):511-5. PubMed ID: 20332694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic manipulation of Nb rat prostatic adenocarcinomas: chemotherapeutic evaluation of autonomous tumors.
    Drago JR; Goldman LB; Maurer RE; Gershwin ME; Eckels DD
    Invest Urol; 1979 Nov; 17(3):203-6. PubMed ID: 500317
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma: a phase II study.
    Izbicki RM; Amer MH; Al-Sarraf M
    Cancer Treat Rep; 1979 Jun; 63(6):999-1001. PubMed ID: 380805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Results of 27 cases with hepatic metastases treated by combination chemotherapy.
    Priestman TJ; Hanham IW
    Br J Cancer; 1972 Dec; 26(6):466-72. PubMed ID: 4647397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer.
    Mouridsen HT; Palshof T; Brahm M; Rahbek I
    Cancer Treat Rep; 1977; 61(1):47-50. PubMed ID: 324620
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
    Chlebowski RT; Hestorff R; Sardoff L; Weiner J; Bateman JR
    Cancer; 1978 Dec; 42(6):2546-52. PubMed ID: 365313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.
    Creech RH; Catalano RB; Mastrangelo MJ; Engstrom PF
    Cancer; 1975 Apr; 35(4):1101-7. PubMed ID: 1116103
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.